REGULATORY COMPLIANCE – Page 10

Poor change control discipline during routine manufacturing – root cause analysis inspectors expect

Recognizing the early signs of poor change control is essential for mitigating risk. Indicators may vary across departments but commonly include:Click to read the full article.

Poor change control discipline during routine manufacturing – FDA/EMA inspection citation risk

Identifying symptoms of poor change control discipline begins at the manufacturing floor or within laboratory settings. Here are key signals that may indicate underlying issues:Click to read the full article.

Uncontrolled SOP changes during scale-up – how to rebuild GMP maturity

Identifying early symptoms is crucial for preventing broader issues that can arise from uncontrolled SOP changes. Key signals include:Click to read the full article.

Inconsistent GMP interpretation during regulatory inspection – FDA/EMA inspection citation risk

Recognizing red flags at the first signs of GMP interpretation inconsistencies is crucial. Symptoms may vary across different roles, but common indicators include:Click to read the full article.

Inadequate GMP training during scale-up – CAPA framework to prevent recurrence

Recognizing the signs of inadequate GMP training is crucial. Symptoms may include:Click to read the full article.

Uncontrolled SOP changes during scale-up – FDA/EMA inspection citation risk

Understanding the early signs of uncontrolled SOP changes is crucial. Look for the following signals:Click to read the full article.

Repeated GMP deviations during internal audit – evidence package for inspection defense

Identifying symptoms of repeated GMP deviations is crucial in ensuring that issues are addressed promptly. Common signals include:Click to read the full article.

API site WHO GMP risk during WHO inspection – avoiding repeat WHO observations

Mitigating API Site Risks During WHO Inspections: A Practical Playbook Pharmaceutical manufacturers face a growing imperative to maintain compliance with WHO Good Manufacturing Practice (GMP) standards. The increasing scrutiny during…

Inadequate WHO GMP training during internal gap assessment – CAPA aligned to WHO standards

The first step in recognizing inadequate WHO GMP training is the identification of symptoms regarding performance and compliance in the manufacturing and testing environments. Common signals include:Click to read the…

Supplier WHO GMP non-compliance during internal gap assessment – CAPA aligned to WHO standards

During internal assessments, certain symptoms may indicate supplier WHO GMP non-compliance. Identifying these signals early can help mitigate risks. Common indicators include:Click to read the full article.

WHO GMP gap identified during internal gap assessment – avoiding repeat WHO observations

Identifying gaps in WHO GMP compliance starts with observing key symptoms in production, quality control, and laboratory environments. Symptoms that typically signify potential compliance issues include:Click to read the full…

Inadequate WHO GMP training during prequalification preparation – CAPA aligned to WHO standards

Understanding the early warning signs of inadequate GMP training is essential for swift intervention. Some common symptoms include:Click to read the full article.